Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha lactalbumin oleic acid - Hamlet Pharma

Drug Profile

Alpha lactalbumin oleic acid - Hamlet Pharma

Alternative Names: Alpha1H; HAMLET; Human alpha-lactalbumin made lethal to tumours

Latest Information Update: 06 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hamlet Pharma AB
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Bladder cancer
  • Preclinical Cancer; Colorectal cancer; Glioblastoma; Skin cancer
  • No development reported Papilloma

Most Recent Events

  • 22 Jul 2019 Adverse events and efficacy data from a phase I/II trial in Bladder cancer released by Hamlet Pharma
  • 21 Jul 2019 Hamlet pharma completes phase I/II trial in Bladder cancer in Czech Republic
  • 20 May 2019 HAMLET Pharma has patent protection for manufacturing and use of alpha lactalbumin oleic acid globally
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top